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DNA copy number alterations (CNAs) are promising biomarkers to predict prostate cancer (PCa) 
outcome. However, fluorescence in situ hybridization (FISH) cannot assess complex CNA 
signatures due to low multiplexing capabilities. Multiplex ligation-dependent probe amplification 
(MLPA) can detect multiple CNAs in a single PCR assay, but PCa-specific probe mixes 
available commercially are lacking. Synthetic MLPA probes were designed to target 10 CNAs 
relevant to PCa: 5q15-21.1 (CHD1), 6q15 (MAP3K7), 8p21.2 (NKX3-1), 8q24.21 (MYC), 
10q23.31 (PTEN), 12p13.1 (CDKN1B), 13q14.2 (RB1), 16p13.3 (PDPK1), 16q23.1 
(GABARAPL2), and 17p13.1 (TP53) with 9 control probes. In cell lines, CNAs were detected 
when the percentage of cancer genome was as low as 30%. Compared to FISH in radical 
prostatectomy (RP) formalin-fixed paraffin-embedded (FFPE) samples (n=18: 15 cancers, 3 
matched benign), the MLPA assay showed median sensitivity and specificity of 80% and 93%, 
respectively, across all CNAs assessed. In the validation set (n=40: 20 tumors sampled in two 
areas), the respective sensitivity and specificity of MLPA compared advantageously to FISH and 
digital droplet TaqMan PCR (ddPCR) when assessing PTEN deletion (FISH: 85% and 100%, 
ddPCR: 100% and 83%) and PDPK1 gain (FISH: 100% and 92%, ddPCR: 93% and 100%). In 
conclusion, this new PCa probe mix accurately identifi s CNAs by MLPA across multiple genes 
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Prostate cancer (PCa) is the most commonly diagnosed vi ceral malignancy in North American 
men and a leading cause of cancer-related mortality 1, 2. PCa has a heterogeneous clinical 
outcome ranging from an indolent disease to a deadly metastatic cancer. Standard treatments for 
localized PCa consist of radical prostatectomy (RP) or radiotherapy, which are often associated 
with significant adverse side effects. Active surveillance, a close monitoring of the disease with 
intent for therapeutic interventions at first sign of progression, has become a viable option for 
patients with low-risk PCa 3. The key challenge in the management of early PCa is to distinguish 
between indolent disease and clinically significant tumors. Current prognostic parameters such as 
pre-operative PSA levels, clinical staging and Gleason grading of biopsy specimens cannot 
accurately predict individual clinical outcome 4, which leads to overtreatment of clinically 
insignificant diseases and under-treatment of aggressiv  cancers with metastatic potential as a 
result of incomplete risk assessment at diagnosis 5. Better prognostic indicators would allow 
immediate treatment of patients with potentially life-threatening cancer and active surveillance 
of patients who would not benefit from immediate or aggressive treatments. Thus far, genomic 
profiling has shed some light on the molecular heterog neity of PCa and has identified potential 
prognostic markers that can improve risk stratification and provide better assessment of disease 
status. Loss of expression of tumor suppressor protein such as PTEN can be assessed on tissue 
section by a standard immunohistochemistry assay and h s been associated with poor clinical 
outcome 6. To assess simultaneously the expression of multiple biomarkers and improve patient 
stratification, RNA-based assays such as Prolaris 7, Oncotype Dx Genomic Prostate Score 8, and 
Decipher genomic classifier 9 have been developed. However, the development of multiplex 
DNA-based assays has lagged behind RNA-based markers even though DNA holds several 









Downloaded for Anonymous User (n/a) at McGill University from ClinicalKey.com by Elsevier on August 10, 2020.
For personal use only. No other uses without permission. Copyright ©2020. Elsevier Inc. All rights reserved.
4 
 
DNA copy number alterations (CNAs) are genomic alter tions consisting of deletion or gain of 
genomic DNA segments ranging from one kilobase to several megabases that may influence the 
function of several genes and regulatory elements 10 and impact disease progression 11, 12. In PCa, 
CNAs are more common than single nucleotide alterations 13, 14 and their frequency increases in 
advanced cancers 13-16. Gain of oncogenes such as MYC and loss of tumor suppressors such as 
PTEN and TP53 are examples of CNAs that are associated with disease progression and may 
serve as prognostic biomarkers in PCa 17-23. Moreover, assessing the CNA status of PTEN would 
improve the outcome prediction of its expression measured by immunohistochemistry 6.
Furthermore, studies suggest that the assessment of a combination of multiple CNAs in primary 
tumors improves patient risk stratification 18, 24-26. The gold standard method for detection of 
CNAs in clinical tissue samples is fluorescence in situ hybridization (FISH) 24. However, FISH 
sensitivity and resolution are probe dependent and implementation for high throughput analysis 
has been limited by the cost of reagents, labor and the small number of CNAs that can be 
assessed in a single assay 27. Given the small amount of tissue obtained from prostate biopsies, 
there is an unmet need for new multiplex assays to apply CNA biomarker signatures in the 
clinical setting. However, the development of such assays based on extracted nucleic acids must 
confront the challenge of prostate tumor tissues heterogeneity that often include benign glandular 
and stromal cells alongside cancer cells. Thus, genomic DNA extracted from such samples 
consists of cancer cell DNA diluted to various degrees with benign cell DNA. 
Multiplex ligation-dependent probe amplification (MLPA) is a multiplex PCR-based CNA 
detection method 27. MLPA probes consist of two “half-probes”, flanked by universal primer 
binding sites, which hybridize next to each other to a specific DNA sequence target (CNA 
region). Upon ligation of the two half probes, which an only occur if the DNA target sequence 
is present in the sample, the complete probe is PCR amplified using fluorescently labeled 
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size and fluorescent PCR products corresponding to target sequences can be separated and 
quantified by capillary electrophoresis. MLPA can assess up to 50 different loci in a single 
reaction with a resolution of 30-60 bp and is compatible with low amounts (50 ng) of fragmented 
DNA extracted from FFPE biopsy samples. This assay i  low-cost, and results can be generated 
within two days using a multi-well format suitable for high throughput analysis. MLPA has been 
used to simultaneously detect multiple CNAs in a variety of cancers 28, 29. However, to our 
knowledge there is currently no PCa-specific probe mix available to assess multiple PCa relevant 
CNAs. In this study, we report the design, validation and application of a PCa specific MLPA 
probe mix that can be used on FFPE samples to assess ten CNAs relevant to this disease. 
 
 
Materials and Methods 
 
Cell lines 
Human prostate cancer cell lines PC-3, DU145, and LNCaP were purchased from American 
Type Culture Collection (ATCC, Gaithersburg, MD) and the LAPC4 cell line was obtained from 
Dr. Robert Reiter, Department of Urology, University of California, Los Angeles. All cell lines 
were cultured in Hyclone RPMI 1640 media (GE Life Sciences, Chicago, IL) supplemented with 
10% fetal bovine serum (Wisent Bioproducts, Saint-Jean-Baptiste, Canada), Gibco 1% 
penicillin-streptomycin, and 2 mM L-Glutamine (Thermo Fisher Scientific, Bedford, MA). 
 
Prostate tissue samples  
This study was approved by the Research Ethics Board f McGill University Health Centre 
(Quebec, Canada, BDM-10-115) and amended to include samples from Kingston General 
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Canada). All RP FFPE specimens were histologically reviewed centrally by pathologists to 
identify the cancer area and assign the final Gleason grade, according to the latest International 
Society of Urological Pathology/World Health Organization recommendations 30. The samples 
from Queen’s University were used to develop the method and hereafter will be referred to as the 
test sample set (n=18: 15 cancers and 3 matched benign areas, Table 1). Tissue cores of 0.6 mm 
were harvested from the same RP FFPE block to extract DNA for MLPA (3 cores) and to build a 
tissue microarray (TMA) used for FISH analyses (3 cores). For the method validation, an 
independent set of RP FFPE tissue specimens (n=40: 20 tumors sampled in two areas, Table 1) 
collected at the McGill University Health Centre were cored (3 x 0.6 mm, 2-3mm in length) for 
DNA extraction in two tumor areas representing the highest (A sample) and lowest (B sample) 
Gleason grade patterns identified by the pathologists. When only one Gleason grade pattern was 
represented, the two sampled areas were assigned to A or B randomly. The FISH on the 




DNA from cell lines was extracted using Qiagen DNeasy Blood & Tissue Kit (Qiagen Inc., 
Toronto, Canada). Two million cells grown in monolayers were detached using Gibco trypsin 
and washed twice with PBS before DNA extraction according to Qiagen manufacturer 
instructions. For FFPE tissue samples, the DNA was extracted from three 0.6 mm cores with a 
modified protocol of the AllPrep DNA/RNA FFPE Kit (Qiagen) as previously described 31. 
 
Normal reference DNA samples 
Commercially available normal female genomic DNA (Promega, Madison, WI), hereafter 
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(McGill University Health Centre) and normal breast lymph nodes (Ontario Tumor Bank, 
Ontario Institute for Cancer Research) were used as reference samples for MLPA experiments.  
To assess the CNA detection limit, commercially avail ble normal male genomic DNA 
(Promega) was used to dilute PC-3 genomic DNA. 
 
MLPA probe selection, design, and synthesis 
 
Due to technical limitation in the synthesis of long oligonucleotides with high coupling 
efficiency, synthetic MLPA probe mixes generally include 20-30 probes 32-34. Thus, to build a 
PCa specific MLPA probe mix and considering the number of synthetic probes that can be 
included, we performed a literature review and select d ten relevant genes (loci) that undergo 
CNA in PCa and are known to be associated with clinical outcome or have the potential to 
improve patient risk stratification. These include th  known oncogene MYC (8q24.21) 17, 21, 23, 
the tumor suppressors PTEN (10q23.31) 18, 20, 22, 35, TP53 (17p13.1) 19, 21, 36, CDKN1B (12p13.1) 
37, 38, and RB1 (13q14.2) 15, 39, genes in loci associated with metastasis such as GABARAPL2 
(16q23.1) 15, 25 and PDPK1 (16p13.3) 40, 41, and genes associated with the previously described 
molecular PCa subtypes 15 CHD1 (5q15-q21.1) 15, 42, 43, MAP3K7 (6q15) 15, 42, 44 and NKX3-1 
(8p21.2) 15 (Table 2).  
For normalization and data analysis, MLPA also requires internal reference probes targeting loci 
that are less likely to undergo CNA. Most synthetic MLPA probe mixes use a commercially 
available reference mix named P200 from MRC-Holland (MRC Holland, Amsterdam, 
Netherlands) for this purpose. The P200 reference mix is unsuitable for PCa since it contains 
probes that target loci commonly deleted in PCa, such as 21q22 (TMPRSS2-ERG fusion) 45-47, 
10q22, 5q31 and 16q24 15, 16. Therefore, three publicly available PCa CNA datasets 15, 16, 26 were 
analyzed to select genes least affected by CNA (≤5%) and were used to design nine new 
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MLPA probes were designed using MLPA Designer 7.91 software (PREMIER Biosoft, Palo 
Alto, CA), according to guidelines provided by MRC-Holland. All genomic sequences were 
obtained from the NCBI Reference Sequences (RefSeq) database. Twenty probes were designed 
for each exon of the selected genes. The GC content was chosen to be between 40% and 65% 
and the Tm was 72 ± 5ºC for all probes. The assay was designed to suit DNA fragments shorter 
than 200 bp typically extracted from FFPE samples 31 and therefore the combined hybridization 
sequences of the 5’ half-probe and 3’ half-probe of all probes were kept under 200 nucleotides.  
The top-ranking probes based on GC content, Tm, hairpin ∆G and probes terminal nucleotide 
sequences were assessed for probe-probe interactions. Probes showing interactions stronger than 
-3 ∆G were replaced with the next ranking exon probes available. In instances that exon probes 
could not be selected, intron probes were designed.  
Two probes for each CNA gene targeting two different genomic regions and one probe per 
reference gene were selected in the final probe mix. Stuffer sequences as previously reported by 
Zhi and Hatchwell 48, were added between the hybridization sequence and the universal primer 
binding sequences of each half-probe to give a unique length to the final probe with at least three 
nucleotide length differences between consecutive probes. The lengths of the complete MLPA 
probes (ligated 5’ and 3’ half-probes including stuffer sequences) were kept under 260 
nucleotides, since longer synthetic probes did not yield reproducible results (data not shown). 
Probe specificity was confirmed by BLAT (https://genome.ucsc.edu/cgi-
bin/hgBlat?command=start, accessed on October 9th, 2017). The presence of known PCa 
mutations and SNPs within the probe target sequence was ruled out using Ensembl Variation 
database 49 and PCa SNP data downloaded from cBioPortal websit, respectively 50, 51.  
All probes were synthesized and purified using standard desalting by Integrated DNA 
Technologies (IDT, Coralville, IA) and received at 4 nmole scale. The 3’ half-probes were 5’ 
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according to the 2013 UCSC Genome Browser assembly (hg38) are available in Table 2. All 
probes were dissolved and diluted in TE1 buffer (10mM Tris-HCl, 1 mM EDTA; pH 8.0). A 
synthetic probe mix was constructed by adding 0.8 µl of 1 µM concentration of each half-probe 
and 1:25 dilution of the CF004-A1 control fragments (Q+D-control fragments, Lot: A1-0715, 
MRC-Holland), allowing assessment of DNA quantity and quality of MLPA reactions. The final 
volume of the probe mix was then adjusted to 600 µl using TE1 buffer. The newly designed 
probe mix was named “PCa probe mix”. 
 
MLPA reaction and analysis 
The MLPA reaction was performed according to the MLPA General Protocol (One-Tube) using 
MLPA kit EK1-FAM (MRC-Holland). Components of the kit and buffers are available in MLPA 
General Protocol (MDP version-007; Issued on 01 March 2019) at the manufacturer website. 
Unless otherwise specified, each experiment included uplicate reactions for each sample and 
four repeats of each reference sample. 
Briefly, for each reaction, 50 ng of DNA in 5 µl ofTE0.1 buffer (10mM Tris-HCl; 0.1 mM 
EDTA; pH 8.2) was used. After initial denaturation at 98oC for 5 min, the hybridization mix (1.5 
µl of PCa probe mix and 1.5 µl of SALSA MLPA buffer per reaction; as per manufacturer 
instructions) was added at room temperature. After d naturation at 95oC for 1 min, the 
hybridization was performed at 60oC for 16 h. The ligation mix (25 µl of ddH2O, 3 µl of Ligase 
buffer A, 3 µl of Ligase buffer B and 1 µl of SALSA Ligase-65 per reaction) were then added at 
54oC followed by incubation at 54oC for 15 minutes and then 98oC for 5 minutes. The 
polymerase mix (7.5 µl of ddH2O, 2 µl of PCR primer mix and 0.5 µl of SALSA polymerase per 
reaction) was added at room temperature and the PCR reaction was carried out for 35 cycles of 
95oC for 30 sec, 60oC for 30 seconds and 72oC for 1 minute followed by a final extension of 20 
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(Cat. No. 2239441) and caps (Cat. No. TCS0803) were used. For detection of the error-rate of 
the assay, another thermal cycler (T100 Bio-Rad, Hercul s, CA), different PCR plates (Cat. No. 
AB0600, Thermo Fisher Scientific), caps (Cat. No. AB0265, Thermo Fisher Scientific), mineral 
PCR oil (Vapor-Lock, Qiagen) and a different referenc  probe mix (P200 – B1, Lot: B1-1215, 
MRC-Holland) were also used. 
Capillary electrophoresis was performed by the Genomics platform of the Institute for Research 
in Immunology and Cancer (IRIC), Université de Montréal using GeneScan 500 LIZ dye Size 
Standard molecular weight marker (Thermo Fisher Scientif c) and ABI 3730 DNA analyzer 
equipped with G5 filter set.  
Coffalyser software (Version 140721.1958, MRC-Holland) was used for fragment and 
comparative analyses of CNAs, using default settings unless otherwise indicated. The manual 
probe recognition method was applied. Intra sample normalization was performed by calculating 
the median value of the test probe over each of the ref rence probes and inter sample 
normalization was performed by calculating the averg  value of the normalized probe signal in 
test sample over each of the reference samples. The classic and the P.I.N.P.2 analysis protocol 
were used for CNA analysis of cell lines and FFPE samples, respectively.  
Four replicates of fresh healthy female genome were us d as a reference population in the 
analysis of cell lines and four replicates of each reference sample (fresh female genome, DNA 
extracted from normal FFPE kidney and breast lymph node reference samples) were used as 
reference population for analysis of FFPE samples. For testing further analysis approaches, probe 
ratios, standard deviations and CNA calls based on cutoff points (probe ratios below 0.65 are 
considered deletion and above 1.3 are considered as gain) and CNA calls based on the 95% 
confidence intervals of probes (as described below) were exported to Microsoft Excel 2017.  
For the 95% confidence interval approach, gain or deletion calls were assigned for each probe 
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below those observed in reference samples. If the 95% confidence intervals in the sample and the 
reference overlapped, normal copy number calls were assigned. In FFPE tissue samples, only 
MLPA calls for gain of MYC and PDPK1 as well as deletion of the remaining eight targeted 
genes were considered as CNAs in the analyses. 
Reactions showing high standard deviation (>10%) in more than four probes were considered to 
fail the quality control (QC) and were repeated (if sufficient DNA was available) or removed 
from the analysis.  
For comparison with existing datasets, the probe ratios resulting from the MLPA analysis of the 
four PCa cell lines were log2 transformed to compare with two CNA datasets generated by 
array-CGH (Array comparative genomic hybridization): Zhao et al 52 and the cancer cell line 
encyclopedia (CCLE) 53. Pearson correlation coefficients between all data points were 
calculated.  
 
Fluorescence in situ hybridization (FISH) 
The TP53 CNA (17p13.1) was assessed using TP53 / CEP 17 FISH probe kit from Abbott 
Molecular (Des Plaines, IL).  
The following BAC clones mapping to the remaining nine target genes were labeled with 
Spectrum Orange dUTP (Enzo Life Science, Farmingdale, NY) using Nick Translation kit 
(Abbot Molecular) and used for FISH: RP11-813D1 (5q1 -5q21.1; CHD1), RP1-154G14 (6q15; 
MAP3K7), RP11-325C22 (8p21.2; NKX3-1), RP11-440N18 (8q24.21; MYC), CTD-2557P6 
(10q23.31; PTEN), RP11-180M15 (12p13.2-p13.1; CDKN1B), RP11-893E5 (13q14.2; RB1), 
RP11-16C11 (16q23.1; GABARAPL2), and RP11-20I23 (16p13.3, PDPK1).  
The following control probes for each chromosome were used: Centromere enumeration probes 
labeled with Spectrum Green CEP6, CEP8, CEP10, and CEP12 (all from Abbot Molecular), 
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(5p12) and pHuR-195 (16qh) labeled with Spectrum Green dUTP. The PTEN CNA in cell lines 
was detected using the XT PTEN/GRID1 probe (Metasystem , Newton, MA). 
Specificity of FISH probes was confirmed on normal metaphase chromosome preparations 
(Molecular Genetics Laboratory, McGill University Health Centre). Metaphase spreads of PC-3 
and LAPC4 cells were prepared for FISH hybridization. Briefly, cells were grown in standard 
culture medium described above supplemented with 1 µg/ml of Invitrogen Colcemid (Thermo 
Fisher Scientific) for three hours and then washed with PBS and detached using Gibco Trypsin. 
After a centrifugation step at 1000 x g for 5 minutes, 5 million cells were resuspended in 2 ml of 
0.56% KCl solution and incubated at room temperature fo  5 minutes. Cells were re-centrifuged 
(1000 x g, 5 minutes) and fixed in 0.5 ml of methanol:glacial acetic acid (3:1) solution before 
being spread on slides and air dried. Slides were then pretreated by incubation in 70% formamide 
and saline-sodium citrate (SSC) solution (0.3 M sodium chloride and 30 mM trisodium citrate, 
pH 7.0) at 75°C for 5 minutes followed by dehydration n ethanol series of 70%, 85% and 100% 
for one minute each. The test and control FISH probes along with the target DNA were 
codenatured at 73°C for 6 minutes and left to hybridize overnight at 37°C using the ThermoBrite 
System (Abbott Molecular). Post-hybridization washes were performed in 2X SSC and 0.3% 
NP-40/0.4X SSC at 73°C for 2 minutes and 1 minute, respectively, followed by a 30-second 
incubation at room temperature in 2X SSC. Dual-color tissue FISH was performed on 5µm 
sections of TMAs or whole tissue blocks as we previously reported 40.  
 
FISH data analysis 
To evaluate copy number status, fluorescent signals were counted in 100 non-overlapping 
interphase nuclei for each case (as identified on crresponding H&E staining for tissues) 
counterstained with ProLong Diamond antifade reagent with DAPI (Thermo Fisher Scientific), 
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and by the presence of two control signals as we previously reported 40. A gene was considered 
homozygously deleted if ≥15% of nuclei had no test locus signal and two control signals. A gain 
was defined as present at a threshold of ≥15% of nuclei containing three or more test locus 
signals and by the presence of two control signals. Images were acquired with an Olympus IX-81 
inverted microscope at 96X magnification, using Image-Pro Plus 7.0 software (Media 
Cybernetics, Rockville, MD). 
 
Digital droplet TaqMan PCR 
Digital Droplet PCR for CNA analysis of PTEN and PDPK1 was carried out using TaqMan 
probes targeting the same regions assessed by the MLPA probes. For the PTEN gene, probe (5’-
/6-FAM/AGAAAGCTTACAGTTGGGCCCTGT/Iowa Black/-3’) and primers (forward: 5’-
TCTGTCGCCATGGCTTATTC-3’, reverse: 5’-CACCAAGACCCTGTCTCAAA-3’) were 
designed to target exon 9 and for the PDPK1 gene, probe (5’/6-
FAM/CGTGTACGGAGTTCCACTTTCCATGA/Iowa Black/-3’) and primers (forward: 5’-
AGCAGCTTACATGTCTGAAGTTA -3’, reverse: 5’-TGTTCAAGAG AGCTACAAAGG-3’) 
were designed to target the intron 10 region. For inter-sample normalization, a probe targeting 
AGO1 (1p34.3) (5’-HEX/ CAAGTCCAGTGACCACACTCCCAG/ Iowa Black-3’, forward 
primer: 5’-GAAGATGATGCTCAACATTGATGG-3’, reverse primer: 5’- 
AGAGCTGGGAGGGATGAG-3’) was used. Test and control probes were respectively labeled 
with 6-FAM (Fluorescein amidite) and HEX (Hexachloro-Fluorescein) dyes (IDT). DNA 
extracted from normal kidney (FFPE tissue) was used as the reference sample. Fresh female 
genome and PC-3 cell line DNA were used as controls.  
The assay was carried out by the Genomics platform of IRIC, Université de Montréal according 
to Bio-Rad TaqMan qPCR instructions (Bio-Rad) with some modifications as described below. 
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500 nM of primers and 250 nM of probes, 2X ddPCR Supermix for probes (no UTP) and 5 
unit/reaction XhoI enzyme (New England Biolabs, Ipswich, MA). Samples were subjected to 
droplet generation by an automated droplet generator. End-point PCR was performed with 
cycling steps as follows: initially an enzyme activa on at 95°C for 10 minutes followed by 50 
cycles of denaturation, annealing and extension (each cycle at 95°C for 30 s; 58°C for 1 min; 
72°C for 30sec; 2.5°C/sec ramp rate) and finally enzyme deactivation at 98° C for 10 min. 
Droplets were read on droplet reader QX200 (Bio-Rad) nd data were analyzed using 
QuantaSoft Software (Bio-Rad) which determines the numbers of positive and negative droplets 
for each fluorophore in each sample. The fraction of p sitive droplets was then fitted to a 
Poisson distribution in QuantaSoft Software (Bio-Rad) to determine the absolute copy number in 
units of copies/μl.  
Average ratios of duplicate reactions were used for normalization. Intra sample normalization 
was done by calculating the ratio of the test probe v r AGO1 reference probe and inter sample 
normalization was done by calculating the normalized probe ratio in the test sample over the 
normalized probe ratio obtained from the kidney refe nce sample. Cutoff for gains (>1.2) and 
deletion (<0.8) corresponded to two standard deviations above and below the average ratio 
obtained from samples (fresh female DNA and tumor DNA from FFPE blocks) with no gains 
and deletions based on MLPA and FISH assays. 
 
Statistical softwares 
Statistical analyses were performed using GraphPad rism version 6, except for the 95% 
confidence intervals calculation and McNemar test, which were done using MedCalc Version 
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Assessment of the performance of designed MLPA probes in presence of normal genome 
 MLPA was selected as a suitable assay to measure CNAs from small amounts of genomic DNA 
that can be extracted from FFPE tumor samples in a multiplex format (Figure 1A). A custom-
made MLPA probe mix including nine control probes targeting CNA quiet loci was designed to 
simultaneously determine the CNA status of ten genes relevant to PCa prognostication (Table 2). 
To assess potential probe-probe interactions, a MLPA reaction was carried out in the absence of 
DNA (water) and showed no peaks in the region corresponding to the designed probes (101 to 
232 bp), confirming the absence of false-positive signals (Figure 1B). As expected, strong 
quantity control Q-DNA probe peaks at 64, 70, 76, and 82 bp, indicated the absence of DNA 
contamination and probe-probe interactions in an otherwise successful PCR reaction.  
In presence of normal genomic DNA, each probe generated one specific fluorescence peak, all 
within the acceptable range of 1000 to 35000 relative fluorescent units (RFU), that appeared on 
capillary electrophoresis 2-4 nucleotides smaller in average than the designed length, which is 
consistent with the results obtained by Stern et al 33 and likely explainable by the negative 
charge-to-mass ratio of the dye 54 (Figure 1C). Consistent with normal copy number values, the 
probe ratios in the fresh normal genomic DNA (4 replicates of both male and female) and FFPE 
(6 replicates of both normal kidney and normal breast lymph node) were respectively between 
0.94 and 1.04 and between 0.9 and 1.07 with less than 5% standard deviation (Figure 1D, 
Supplemental Table S1). The false-positive rate of the new assay was assessed in six separate 
experiments of MLPA (96 repeats each) using the PCa test probes mix with the designed 
reference probes or the commercial P200 – B1 referenc  probe mix on fresh normal genomic 
DNA. Each experiment assessed potential sources of variation due to the thermal cycler, the 
experimenter, the PCR plates, the caps and the presnc  of a mineral oil overlay to minimize 
evaporation. On average across the six experiments, the false CNA call was very low, 
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probes in each experiment (total of 2,784 probes; 95% confidence interval: 0.46% - 1.31%). The 
error rate was independent of probes or any of the assessed parameters mentioned above and 
appeared to be intrinsic to the assay.  
 
Detection of CNAs in PCa cell lines by MLPA 
The PCa probe mix was next applied to fresh genomic DNA extracted from PCa cell lines (PC-3, 
DU145, LNCaP, and LAPC4). The Pearson correlation between the probe ratios of duplicate 
reactions was 0.985 (95% confidence interval: 0.978 – 0.989, p <0.0001). Reliability of the assay 
was assessed by repeating MLPA performed on PC-3 genom  in ten separate experiments which 
showed consistent CNA calls (Fleiss’ Kappa= 0.79, 95% confidence interval: 0.72 – 0.85, p 
<0.0001). 
In all probes, with the exception of CHD1 intron 1, a positive Pearson coefficient of correlation 
was seen when comparing the log2 transformed probe ratios generated from MLPA analysis of 
the four cell lines and those obtained from the twopublished array-CGH datasets of Zhao et al 52
and the cancer cell line encyclopedia (CCLE) 53 (Table 3). Of note, MLPA CHD1 intron 1 probe 
targets the cytoband 5q21.1 while the exon probe targe s 5q15 as the array-CGH probe. 
Moreover, the correlation coefficients between the MLPA ratios obtained from probes targeting 
the same gene were all above 0.7, with the exception of PDPK1 (0.56). The correlation 
coefficients that are statistically significant are indicated in Table 3. 
Considering the standard cutoff for gain and deletion, MLPA detected previously reported CNAs 
such as MYC gain, PTEN homozygous deletion, and NKX3-1 (exon 2c probe) hemizygous 
deletion in PC-3 cells (Figure 2A, upper panel) as well as deletions of CDKN1B and CHD1 
(intron 1 probe) in LAPC4 cells (Figure 2A, lower panel). Of note, the NKX3-1 and CHD1 
deletions were respectively identified in PC-3 and LAPC4 cells by both probes targeting each of 
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reported hemizygous deletion of TP53 in PC-3 cells 55 was called by the confidence interval 
approach, but completely missed when considering the fixed cutoff. These observations 
indicated that the sensitivity of the MLPA assay is increased by using the 95% confidence 
interval instead of a fixed cutoff for calling the CNAs.  
Intriguingly, ratios of probes targeting exon 9 of PTEN and NKX3-1 suggested a single copy gain 
of these genes in LAPC4 (Figure 2A, lower panel). To confirm these observations, the 
commercially available PTEN probe mix targeting exons 1 to 9 of the gene and flanking genes at 
10q23.31 (MRC-Holland) was applied on both cell lines. As expected and in agreement with the 
literature 56, a deletion from exons 3 to 9 of PTEN was detected in PC-3 (Figure 2B, upper panel) 
and one copy gain (exons 1-9) was observed in LAPC4 (Figure 2B, lower panel). 
Further validation was performed by FISH analysis on PC-3 and LAPC4 metaphase spreads with 
XT PTEN/GRID1 probe (Metasystems) that targets the distal region of the PTEN gene from 
exon 4 (red), the chromosome 10 centromere (aqua) and GRID1 (green) located at 10q23.1 
between PTEN and the centromere. In PC-3 cells, an average of 3.6 green and 4.6 aqua signals 
were detected per nucleus with no red signal, suggesting a PTEN deletion with a gain of 
chromosome 10 centromere (Figure 2C). In LAPC4, the 4.3 average red and green signals 
suggested a gain at 10q region including both the PTEN and GRID1 genes as well as a 
chromosome 10 centromere duplication with an average of 3.3 aqua signal per nucleus (Figure 
2C).  
Using MYC targeting probes, FISH in PC-3 showed an amplificat on with an average of 12.1 
(red) signals per nucleus along with a 2.9 (green) c tromeric signals for chromosome 8 (Figure 
2C). In LAPC4, FISH suggested a MYC and a chromosome 8 centromere amplification with an 
average of 3.9 signals per nucleus for both test and co trol probes (Figure 2C). For both genes 
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illustrated with the LAPC4 cells, MLPA, like other ratio-based CNA assessment method, can 
detect genomic imbalances, but balance ploidies result in normal probe ratios (undetected).  
 
Assessment of the CNA detection limit  
In the context of prostate tumor tissues heterogeneity and to estimate the minimum content of 
cancer cell DNA to accurately call CNAs with MLPA, a series of samples containing increasing 
percentages of PC-3 DNA (0-100%) over normal human ale genomic DNA was used as a 
template for MLPA. Fresh female genome was used as the reference sample. Using pre-defined 
cutoffs to call CNAs, amplification of MYC, deletion of PTEN and NKX3-1, and one copy gain 
of CHD1 (exon 35 probe) could be accurately detected when t  PC-3 genome was at least at 
10%, 60%, 90%, and 80%, respectively (Figure 3A-D). However, if the CNA calls are made 
based on the 95% confidence interval, all deletions a d gains can be detected when the 
percentage of PC-3 genome is as low as 30% while MYC amplification is still detectable at 10% 
(Figure 3A-D). Since tumor samples could have variable tumor content with different levels of 
CNAs, a highly sensitive approach is required to accurately detect these alterations. This is 
especially important in prognostic assays on low-grade tumors that often have lower tumor 
contents and low CNA levels. The 95% confidence intrval approach would thus appear more 
suitable to call CNAs in clinical samples. 
 
Detection of CNAs using the MLPA designed probe mix in FFPE prostate tumor samples  
MLPA was performed in duplicate reactions on all samples of the test sample set. To account for 
the range of variability expected in FFPE clinical s mples and to match their DNA quality, we 
opted to include two FFPE extracted DNA references (normal breast and kidney) in addition to 
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FISH for the genes assessed by MLPA was performed on all corresponding samples represented 
in a TMA. 
Since each gene is targeted by two probes in the PCa probe mix and duplicate reactions were 
performed for each sample, various combinations of one or two probes in one or both replicates 
were considered to make the final CNA call for a given sample. To explore different 
normalization schemes for determining the CNA calls per reaction, we first normalized all 
reactions against the average ratio of the three DNA reference samples. In the second 
normalization scheme, we normalized all reactions against each of the three DNA reference 
samples separately, yielding three CNA data points per replicate reaction. We further explored 
whether conventional cutoff points, or the 95% confidence interval were best suited to call the 
CNA in each normalization scheme. Similar to the results obtained with cell lines, a lack of 
sensitivity of cutoff points in detection of CNAs called by FISH was evident (Supplemental 
Table S2, approaches 1 to 8). Based on the 95% confidence interval, the sensitivity of assays 
remained low when the data were normalized against the average value of the three reference 
samples (Supplemental Table S2, approaches 9 to 12). However, the sensitivity, based on the 
95% confidence interval, was improved when the dataset was normalized against each reference 
sample separately and the alteration was detected in at least two of the three separately reference-
normalized datasets (Supplemental Table S2, approaches 13-16). Although the sample size was 
limited, results appeared optimal for most CNAs with approach 14, yielding a median sensitivity 
of 80%, specificity of 93% and accuracy of 89% (Supplemental Table S2). With this approach, 
the data is normalized against each of the three ref rence DNA samples separately 
(Supplemental Figure S1). CNA in a gene was thus defined when both duplicate reactions show 
the same CNA in at least one of the probes targetin the gene and in at least two of the three 
normalizations. Figure 4A illustrates final MLPA CNA calls (based on approach 14) and the 
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is shown in Figure 4B for sample (7-C) in which thedeletions of NKX3-1, PTEN and RB1 were 
also called by FISH (Figure 4C).  
As illustrated in Figure 4A, the three benign samples were CNA quiet. While one of the benign 
samples (6-B) did not show any CNA, sample 1-B showed GABRAPL2 deletion which was not 
seen in the corresponding tumor (1-C). The third benign sample (10-B) showed RB1 deletion 
which was also detected in the corresponding cancer sample 10-C. However, no CNAs were 
detected by FISH in the benign samples.  
In cancer samples, heterogeneity was evident among surveyed genes, ranging from none in 
sample 2-C to six in sample 13-C as measured by MLPA (Figure 4A). The highest CNA 
frequency were for RB1 (9/15, 60% in both MLPA and FISH) and NKX3-1 (7/15, 47% in both 
MLPA and FISH), whereas the lowest CNA frequency was for PDPK1 (no CNA was detected 
with either method) and TP53 (1/15, 7% in both methods). The data generated by the nine 
reference probes were examined for the presence of CNAs which were detected only for 
ANKRD36B_Int44 (3/18, 17%) and TIMM10_E3 (1/18, 6%, Supplemental Table S3). 
To validate this analysis approach, the same experimental design was used to perform MLPA on 
genomic DNA extracted from 20 RP-FFPE independent cases in the validation sample set. Each 
case was represented by two samples, A and B corresp nding to the highest and the lowest 
Gleason grade pattern, respectively. All samples pased the QC and were included in the 
analysis.  
Given our laboratory interest in PTEN and PDPK1 as prognostic biomarkers in PCa patients 18, 
41, FISH was performed for these two genes on full sections of the FFPE blocks of this sample 
set targeting the area where tumor tissue cores were ha vested for DNA extraction. Digital 
droplet TaqMan PCR assays were also performed to survey PTEN and PDPK1 CNAs in 17 
samples with the same DNA extracts used for MLPA (Supplemental Table S4). Figure 5A shows 
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profile for sample 23-C along with FISH for PTEN and PDPK1 is presented in Figures 5B and 
5C. As MLPA and FISH, digital droplet TaqMan PCR results confirmed the deletion of PTEN 
and gain of PDPK1 with a probe ratio of 0.48 and 1.24, respectively (Supplemental Table S4). In 
this validation sample set, deletions of NKX3-1 (25/40, 63%) and RB1 (21/40, 53%) were the 
most frequent CNAs detected by MLPA, while PDPK1 gain (5/40, 13%) was the least common, 
similar to results observed in the test set. 
CNAs detected by the reference probes in the validation set were found mostly in 
ANKRD36B_Int44 (5/40, 13%), CYP2B6_Int2 (4/40, 10%) ATP10A_E20 (4/40, 10%) and 
TIMM10_E3 (3/40, 8%, Supplemental Table S5). The maxi um number of reference genes 
affected by CNA per sample was two and observed in only two samples. Compared to FISH, the 
sensitivity and specificity of MLPA to call a PTEN deletion were respectively 85% and 100%. 
MLPA was able to detect PDPK1 gain with a sensitivity of 100% and a specificity of 92%. 
Compared to TaqMan, MLPA showed a sensitivity of 100% and a specificity of 83% in 
detecting PTEN deletion and a sensitivity of 67% and a specificity of 93% in detection of 
PDPK1 gain. However, if we consider the MLPA CNA calls based on the PDPK1 intron 10 
probe only, which assesses the same region targeted by the digital droplet TaqMan PCR PDPK1 
probe, the sensitivity and specificity to detect the PDPK1 gain reach 100% and 93% 
respectively.  
The impact of sampling was investigated by comparing the CNA patterns of tumor samples A 
and B taken from the same FFPE prostate block of each c se. No significant differences in CNA 
calls was observed between samples A and B (McNemar's test p > 0.4, Supplemental Table S6). 
 
Discussion   
A detailed molecular classification of PCa and its associated prognostic value rely on the 
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sections, is not suitable for high-throughput assesment of CNA signatures. Standard array-CGH 
method and whole genome next generation sequencing (NGS) allow a genome-wide survey of 
CNAs but the amount and the quality of DNA required cannot be obtained from FFPE prostate 
biopsy specimens. Variations of the array-CGH method such as OncoScan microarray system 57 
and targeted NGS 58 allow the call of CNAs out of small amounts of DNA extracted from FFPE 
tissue samples. These methods can be very comprehensive and well suited to explore the 
genomic landscape of tumors but would often require further confirmation for a definitive 
diagnosis. MLPA is a well-established method to call CNA widely used in human genetic test 
centres and considered as one of the gold standards which are used to validate new NGS-based 
tests 59. In laboratories already offering genome-wide testing, MLPA assay may serve to rapidly 
confirm NGS and array-CGH findings. Moreover, the MLPA assay is flexible and new probes 
can be added or replaced to suit specific needs. For biomarker signatures application, a genome-
wide survey is often not necessary and MLPA may be considered as a suitable and more 
affordable alternative to NGS and arrays-CGH allowing the analysis of large number of samples 
simultaneously. The low cost of MLPA can be particularly advantageous in the context of 
research work and clinical laboratory with limited resources. Compared to NGS, MLPA requires 
simpler analyses that translate into a faster turnaround time. Performed in a single PCR tube, 
MLPA requires only a thermal cycler and a standard capillary electrophoresis system. MLPA 
technology was thus selected for our new assay amenbl  to prostate biopsy material and filling 
the gap between biomarker research discovery and cli ical application.  
A synthetic probe mix was designed specifically forCNA detection in PCa targeting ten 
commonly altered genes that have the potential to serve as biomarker. This custom-made PCa 
specific probe mix was capable of accurately detecting CNAs in various samples with low error-
rate. Using a synthetic DNA service with a high coupling efficiency of 99.5% (Ultramer DNA 
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probe mix while allowing an increased length of thesynthetic probes from 156 nucleotides 
reported by Stern et al 33 to 232 nucleotides. The performance of these probes was validated by 
the reproducibility of the results obtained and thelow standard deviation of all probes in the 
probe mix when using both fresh and FFPE extracted DNA. Our findings are in agreement with a 
previous report showing that synthetic probes gave comparable results to M13 bacteriophage 
derived probes used in commercially available probe mixes 33. Based on our experience when 
using a coupling efficiency of 99.5%, synthetic MLPA probes of a length of up to 250 
nucleotides might be used to generate highly reproducible results and allow the inclusion of a 
larger number of probes in the assay. 
We further improved and customized the probe mix by designing nine different reference probes 
less likely to be affected by CNA based on reported PCa datasets. The rationale was to account 
for possible genomic instability of cancer cells that could result in random CNAs and the 
incompatibility of PCa samples with commercially available reference probes mixes such as 
P200. Although infrequent CNAs were detected by our reference probes, they did not 
compromise the analyses as there was an ample number of CNA-free references for the 
normalization of each clinical sample. Furthermore, as we and others have observed 33, a higher 
number of reference probes allows for better normalization, higher reproducibility of results and 
smaller standard deviation across different samples 33, 60. Designing customized reference probes 
with an average distance of 4 nucleotides apart also al owed us to include more test probes in our 
PCa-specific probe mix than P200 probes, which have an average of 6 nucleotides apart and do 
not allow inclusion of more than 17 probes per reaction. Furthermore, for more accurate CNA 
detection, two probes per gene were used in the design process to assay each of the ten chosen 
target genes. The rationale stems from previous studies showing that MLPA probes targeting the 
same regions could yield different results 60, 61. Bendavid et al. 62 used two different MLPA 
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both kits. Alterations that were only seen by one of the kits were further confirmed by qPCR. 
Altogether, this supports that more than one probe per target region may allow better CNA 
detection, especially in tumor samples. The use of duplicate reactions in the experimental design 
was advantageous to reduce false-positive results and yielded better reproducibility. We reasoned 
that results would be reliable if the CNA was detected in both replicates. Further analysis 
confirmed high sensitivity and specificity of MLPA duplicate reactions in detection of CNAs 
compared to FISH data. In addition, a high correlation between duplicate reactions was observed 
in all experiments. The results also demonstrated that this MLPA assay performed in various 
experimental conditions yielded a lower rate of false-positive results with an average: 0.89% of 
probes used in each experiment compared to 1.7% reported with commercially available probe 
mixes 62.  
To investigate the accuracy of CNA detection by the designed probe mix, we compared the CNA 
results obtained from MLPA to published array-CGH CNA results of PCa cell lines. Although 
these studies have used a different technique with different set of probes with a lower resolution 
than MLPA, our results are consistent with previous reports 60 and show a positive correlation 
between MLPA and array-CGH data, except for the CHD1 intron 1 probe. CHD1 is a large gene 
(74,569 bp) that spans over two cytobands (5q15-5q21.1). A CNA that would not span the entire 
CHD1 gene in some cell lines such as PC-3 could potentially explain a lack of positive 
correlation of the MLPA intron probe (5q21.1) while the exon probe (5q15) correlates with 
array-CGH (5q15). Accordingly, the CNA would extend over both cytobands in LAPC4 cell line 
as both probes correlate. Testing this hypothesis could be done by mapping the CNA area in 
those cell lines with multiple MLPA probes. Nevertheless, both probes were effective at 
detecting 18 out of 20 CHD1 deletions identified by MLPA in our clinical samples and the 
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While these results indicate that MLPA is capable of detecting copy number imbalances in 
homogeneous samples such as cell lines, the accurate detection of genomic alterations in 
heterogeneous samples such as prostate primary tumors is more challenging. It is not specific to 
MLPA as most genomic assays that use DNA extracted from heterogeneous tumors face the 
same limitations. This was reported by Schwab et al. 60 to explain discrepancies observed 
between MLPA and FISH. The main reason for such discrepancies is intrinsic to the prostate per
se, and the heterogeneous tumor content used for genomic DNA extraction which contain tumor 
DNA mixed with varying proportions of DNA from surrounding benign glands and stroma. 
Furthermore, when there is a low percentage of tumor cells with CNA in samples, due to the 
same dilution effect, genomic assays are not capable of accurately detecting alterations. To 
overcome this limitation, we used the 95% confidence interval for each probe within the 
reference population and test samples to detect CNAs. This approach has the advantage of 
calculating the range of variations seen for each locus in reference samples and detecting 
alterations outside what is normally seen in healthy tissues, thereby providing a more accurate 
measurement of CNAs. Thus, using the confidence interval approach, we were able to capture 
CNAs when the PC-3 genome was diluted up to 30%. When compared to FISH, this method of 
analysis of MLPA data on the test clinical samples resulted in a median sensitivity of 80% and 
specificity of 93% compared to the conventional cutoff points approach with the sensitivity of 
14% and specificity of 100%. Even when analyzing cell lines, we noticed that when using cutoff 
points, the previously reported CNAs such as deletion of TP53 in PC-3 was completely missed 
or called only by one of the two probes for the deletion of NKX3-1 in PC-3 and CHD1 in 
LAPC4. However, when using the 95% confidence interval, all these CNAs were readily 
identified which further supports the use of this approach over fixed cutoff points. 
In both test and validation sets, the number of CNAs varied across the samples as reported in 
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FISH were RB1 and NKX3-1 deletion, a finding in agreement with previous literature 15 and 
consistent with reports suggesting that inactivation of these two tumor suppressors occurs early 
in prostate carcinogenesis 63, 64. Two out of three benign prostate samples showed a single CNA 
each by MLPA, respectively a GABARAPL2 and a RB1 deletion, which were not detected by 
FISH. The benign samples of this study were all from PC patients and the RB1 deletion was also 
detected in the corresponding tumor sample. Althoug false positive results cannot be excluded, 
genomic alterations have been detected in morphologically benign prostate tissues that were 
compatible with field effects in a context of multifocal PCa 65. Profiling additional samples taken 
from multiple areas of tumoral and corresponding benign prostate tissues as well as benign 
samples from non-cancer patients would be warranted to confirm this hypothesis.  
When comparing the results of MLPA and FISH in the test and validation samples, we observed 
good concordance between the two types of assays. Yet discrepancies exist in some prostate 
samples, with MLPA revealing CNAs but not FISH and vice versa. The dilution effect can 
reduce the sensitivity of MLPA as discussed above and unsuspected DNA sequence variations at 
the probe hybridizing site may lead to MLPA false positive results 66. However, the size and the 
location of the targeted DNA region by FISH and MLPA probes may account for the 
discrepancies between both techniques. MLPA with its small probe size allows the mapping of 
CNAs at higher resolution than large FISH probes. Including more MLPA probes per gene or 
using FISH probes that target different areas of the CNA region can help resolve the observed 
discrepancies. 
 
To circumvent any differences linked to probe genomic location and to tumor areas, digital 
droplet PCR TaqMan assays targeting the same genomic reg ons and performed on the same 
DNA extracts showed a high concordance with MLPA results. This further showed the 
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capability and, in this case, only one reference probe was used, whereas the designed MLPA 
assay used nine different reference probes, thereby allowing more accurate normalization.  
We also assessed CNA frequencies in different Gleason grade patterns of the same samples in 
our small validation sample set and did not observe significant differences, thereby suggesting 
negligible intra-tumor CNA heterogeneity in the assessed genes in primary tumors. A more 
robust study with a larger sample size that would include a wider range of Gleason patterns is 
needed to confirm these results.  
Taken together, we have designed and rigorously tested a MLPA-based assay using a fully 
synthetic probe mix. DNA extracts from three 0.6 mm punches (2-3 mm length) from FFPE 
clinical samples were used to simulate needle biopsies, as obtained before diagnosis. The assay 
was capable of detecting CNAs with high sensitivity and specificity compared to FISH. This 
demonstrates the potential compatibility and applicability of the assay on clinical biopsy samples 
for the detection of most common CNAs, thereby opening the door to a better prognosis based 
on CNA profiles. Future investigations should aim to confirm these findings on actual prostate 
diagnostic biopsies and may require a macrodissection of the tumor foci from nearby normal 
glands since the tumor cell content is expected to be less than in RP blocks used for this study. 
Furthermore, the cost is low, our estimate being 7.90 $CAD (6$ USD) per reaction which 
includes the cost of probe synthesis, lab materials, MLPA kits, and capillary electrophoresis. 
MLPA does not require other sophisticated instruments or analysis approaches. The effectiveness 
of this designed probe mix and analysis approach was validated using a small number of clinical 
PCa samples. Further validation on a larger cohort with adequate clinical follow-up data is 
necessary to determine the impact of these CNAs and utility of the assay for prognosis. This 
assay shows potential for clinical application, and by identifying CNAs relevant to poor 
prognosis could aid clinicians and patients in decision-making in view of an optimal 
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Figure 1: Performance of the newly designed MLPA probes in presence of normal genomic 
DNA. (A) Schematic representation of MLPA reaction. No anneali g takes place in absence of 
target DNA (left panel) while in presence of the target sequence, the two MLPA half-probes 
anneal to the DNA next to each other (middle and right panels). After a ligation step, the 
complete probes are amplified using fluorescently labe ed primers. The amount of fluorescent 
signal is correlated with the copy number of the target sequence. (B, C) Electropherogram of 
PCa probe mix in (B) no-DNA control reaction and in (C) presence of normal genome. Relative 
fluorescent units (RFU) are shown for probes from left to right according to their length. Probes 
are identified at the top of their respective peak. (D) MLPA profile of normalized probe ratios in 
normal genome. The upper blue line is the cut-off fr gain and the red for deletions set at 1.3 and 
0.65, respectively.  Reference probes are marked by an asterisk at the top of the probe name. 
 
Figure 2: Detection of CNAs in PC-3 and LAPC4 cell lines. (A, B) In MLPA ratio charts, 
probes in blue and red correspond to gain and deletion based on the standard cut-off point of 
above 1.3 and below 0.65, respectively. Probes in purple show gain or deletion based on the 95% 
confidence interval only. Reference probes are marked by an asterisk at the top of the probe 
name. (A) MLPA results of PC-3 (upper panel) and LAPC4 (lower panel) cell lines using the 
designed PCa probe mix. The red and the blue box highlights respectively the PTEN deletion in 
PC-3 and the PTEN gain in LAPC4. (B) As in (A), but showing the MLPA profiles of PC-3 and 
LAPC4 cell lines using commercial PTEN probe mix (P225-PTEN, D2-0315, MRC-Holland). 
(C) FISH results of PTEN and MYC on metaphase spreads of PC-3 and LAPC4 cell lines. The 
PTEN FISH probe targets three regions of chromosome 10 (XT PTEN/GRID1 probe, 
Metasystems). The red signal corresponds to the PTEN gene, the green signal represents the 
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and the centromere control for chromosome 8 is green. The average number of signals detected 
and the test probe over control probe counts ratio is indicated on each FISH picture (96x 
magnification). 
 
Figure 3: Using 95% confidence interval of probes improves CNA detection limit of MLPA. (A, 
B, C, D) Probe ratio values are plotted against percentage of PC-3 genome for (A) MYC, (B) 
PTEN, (C) NKX3-1 and (D) CHD1. Dashed lines show the standard cut-off points for gains and 
deletions based on probe ratios at 1.3 and 0.65, respectively. The solid lines show the cut-off 
points for gains and deletions based on 95% confidece interval of the probes in the reference 
DNA. 
 
Figure 4: CNA profiles of the test sample set. (A) Final MLPA and FISH CNA calls in the test 
sample set. Patient ID is followed by C for cancer or B for benign sample. (B) Example of 
MLPA results for one sample (7-C) which shows deletions of NKX3-1, PTEN and RB1. Probes 
in red show deletion, according to the 95% confidence interval method. Reference probes are 
marked by an asterisk at the top of the probe name. (C) FISH results for sample 7-C showing 
gene specific signal in red and control signal in green for the 10 loci assessed. Deletions in 
NKX3-1 and RB1 (hemizygous) and PTEN (homozygous) are indicated with arrows (96x 
magnification). 
 
Figure 5: CNA calls in the validation sample set. (A) Final MLPA CNA call for all genes 
assessed along FISH and digital droplet TaqMan PCR (a subset of samples) results for PTEN and 
PDPK1 genes. Patient ID is followed by C (cancer) and either A or B (highest or lowest Gleason 
pattern area of the tumor, respectively). (B) MLPA profile of sample 23-C-A of the validation 
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MYC and PDPK1 in blue, according to the 95% confidence interval method. Reference probes 
are marked by an asterisk at the top of the probe name. (C) Representative images of FISH 
results for sample 23-C-A confirming the PTEN deletion and PDPK1 gain detected by MLPA. 
White arrows show control green signals in absence and presence of multiple gene specific red 
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Table 1: List and characteristics of samples used in this study 
ID 
Type of the 
Core  
Reviewed 







1-C Cancer 4+5 85 Test 
1-B Benign N/A 0 Test 
2-C Cancer 5+4 85 Test 
3-C Cancer 4+3 50 Test 
4-C Cancer 3+4 85 Test 
5-C Cancer 4+5 90 Test 
6-C Cancer 4+3 70 Test 
6-B Benign N/A 0 Test 
7-C Cancer 4+5 70 Test 
8-C Cancer 3+4(5) 75 Test 
9-C Cancer 3+4 85 Test 
10-C Cancer 4+3(5) 90 Test 
10-B Benign N/A 0 Test 
12-C Cancer 4+3(5) 90 Test 
13-C Cancer 4+3(5) 85 Test 
14-C Cancer 4+5 80 Test 
16-C Cancer 5+4 80 Test 
18-C Cancer 4+5 80 Test 
19-C Cancer 4+3(5) 95 Validation 
20-C Cancer 4+4 90 Validation 
21-C Cancer 4+5 90 Validation 
22-C Cancer 4+5 90 Validation 
23-C Cancer 4+4 75 Validation 
24-C Cancer 4+3 75 Validation 
25-C Cancer 4+4 90 Validation 
26-C Cancer 4+5(3) 85 Validation 
27-C Cancer 4+3 90 Validation 
28-C Cancer 3+4 70 Validation 
29-C Cancer 4+5 85 Validation 
30-C Cancer 4+3 80 Validation 
31-C Cancer 3+4 80 Validation 
32-C Cancer 3+4 65 Validation 
33-C Cancer 4+5 90 Validation 
34-C Cancer 3+4 80 Validation 
35-C Cancer 4+3(5) 70 Validation 
36-C Cancer 4+3 80 Validation 
37-C Cancer 4+3(5) 90 Validation 
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Table 2: List and characteristics of designed PCa specific MLPA probe mix 





CHD1 Intron 1 CNA 05q15 98927383-98927458 200 
CHD1 Exon 35 CNA 05q21.1 98856501-98856587 132 
MAP3K7 Exon 17 CNA 06q15 90516154-90516215 125 
MAP3K7 Exon 14 CNA 06q15 90523700-90523761 164 
NKX3-1 Exon 2c CNA 08p21.2 23679195-23679260 188 
NKX3-1 Exon 2 CNA 08p21.2 23679829-23679894 152 
MYC Exon 1 CNA 08q24.21 127736564-127736621 101 
MYC Exon 3 CNA 08q24.21 127740610-127740671 184 
PTEN Exon 9a CNA 10q23.31 87966936-87966999 109 
PTEN Exon 9b CNA 10q23.31 87968061-87968130 140 
CDKN1B Intron 1 CNA 12p13.1 12714777-12714852 156 
CDKN1B Exon 1 CNA 12p13.1 12717331-12717394 180 
RB1 Exon 18 CNA 13q14.2 48453031-48453090 105 
RB1 Exon 23 CNA 13q14.2 48465212-48465273 172 
PDPK1 Exon 14 CNA 16p13.3 2597685-2597741 121 
PDPK1 Intron 10 CNA 16p13.3 2584302-2584368 220 
GABARAPL2 Exon 3 CNA 16q23.1 75568131-75568188 168 
GABARAPL2 Intron 3 CNA 16q23.1 75573764-75573839 196 
TP53 Exon 5 CNA 17p13.1 7674901-7674962 136 
TP53 Exon 4 CNA 17p13.1 7675285-7675346 117 
          
     ANKRD36B Intron 44 Reference 02q11.2 97495557-97495632 232 
MGAT1 Exon 3 Reference 05q35.3 180790824-180790885 160 
TIMM10 Exon 3 Reference 11q12.1 57528778-57528839 204 
METTL1 Intron 1 Reference 12q14.1 57774661-57774736 144 
IPO4 Exon 30 Reference 14q12 24180336-24180397 176 
ATP10A Exon 20 Reference 15q12 25680143-25680204 192 
PIGW Intron 1 Reference 17q12 36533015-36533090 129 
ZNF91 Intron 4 Reference 19p12 23350707-23350774 113 
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Table 3: Correlation of log2 transformed probe ratios between PCa specific MLPA probe mix, and array-CGH studies 
          
Gene Method Study/Probe 







CCLE 53  
r between 
MLPA 




Zhao et al 52 (exon 35) 0.81 -0.42 -1.07 -0.48 
   
CCLE 53 0.49 0.17 0.09 N/A 0.99 
  
         
MLPA 
CHD1 Intron 1 -0.12 0.03 0.27 -0.96 -0.13 -0.89 
 
CHD1 Exon 35 0.44 0.07 0.16 -0.43 0.50 0.91 0.78 




Zhao et al 52 (exon 4) -0.67 -0.35 -1.40 -0.45 
   
CCLE 53 -0.50 -0.29 -1.21 N/A   1.00* 
  
         
MLPA 
MAP3K7 Exon 14 -0.18 -0.54 -0.55 -0.20 0.40 0.32 
 
MAP3K7 Exon 17 -0.07 -0.55 -0.48 -0.02 0.30 0.16   0.98* 




Zhao et al 52 (exon 2) -0.40 -0.30 0.17 -0.06 
   
CCLE 53 -0.47 0.12 0.09 N/A 0.60 
  
         
MLPA 
NKX3-1 Exon 2 -0.56 0.04 0.19 0.43 0.72 0.97 
 
NKX3-1 Exon 2c -0.73 0.19 0.28 0.27 0.71 0.99 0.94 




Zhao et al 52 (exon 3) 0.69 -0.10 -0.01 -0.17 
   
CCLE 53 0.95 0.32 0.09 N/A 0.93 
  
         
MLPA 
MYC Exon 1 0.84 0.23 0.17 0.29   0.95* 0.98 
 
MYC Exon 3 3.14 0.19 -0.14 -0.20   0.98* 0.99   0.98* 




Zhao et al 52 (exon 1) -0.36 -0.03 -0.55 0.05 
   
CCLE 53 -2.40 0.15 -0.91 N/A 0.55 
  
         
MLPA 
PTEN Exon 9a -3.74 -0.12 -2.65 0.59 0.88 0.95 
 
PTEN Exon 9b -5.64 0.01 -0.50 0.47 0.45 0.94 0.82 




Zhao et al 52 (exon 3) -0.29 -0.54 -0.13 -0.73 
   
CCLE 53 -0.51 -0.29 0.06 N/A 0.50 
  
         
MLPA 
CDKN1B Intron 1 -0.47 -0.34 0.19 -0.75 0.84 0.98 
 
CDKN1B Exon 1 -0.55 -0.53 0.09 -0.92 0.90 0.93   0.99* 




Zhao et al 52 (exon 27) 0.23 0.15 0.15 0.29 
   
CCLE 53 -0.05 -0.31 -0.23 N/A 0.95 
  
         
MLPA 
RB1 Exon 18 0.03 -0.22 -0.14 0.30   0.98*   1.00* 
 
RB1 Exon 23 -0.14 -0.67 -0.35 -0.18 0.76 0.94 0.77 




Zhao et al 52 (exon 14) 0.34 0.12 0.27 0.16 
   
CCLE -0.53 -0.35 0.07 N/A -0.09 
  
         
MLPA 
PDPK1 Intron 10 -0.11 -0.22 0.17 -0.24 0.57 0.84 
 
PDPK1 Exon 14 0.04 -0.32 0.15 0.08 0.62 0.44 0.57 




Zhao et al 52 (exon 4) -0.10 0.02 -0.07 0.05 
   
CCLE 53 -0.50 0.10 -0.04 N/A 0.84   
         
MLPA 
GABARAPL2 Exon 3 -0.04 0.09 -0.07 -0.14 0.01 0.54 
 
GABARAPL2 Intron 3 -0.31 0.21 -0.03 -0.30 0.22 0.97 0.81 




Zhao et al 52 (exon 17) 0.01 0.52 0.31 0.22 
   
CCLE 53 -0.50 0.16 0.08 N/A 0.95 
  
         
MLPA 
TP53 Exon 4 -0.43 0.24 0.05 0.20 0.84 0.99 
 
TP53 Exon 5 -0.41 0.35 0.05 0.06   0.97* 0.96 0.94 
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†For MLPA probes, except for DU145 cell line which is represented by one replicate, average probe ratios obtained from duplicate 
reaction of cell lines were used. 
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